APO Research
Talk to an analyst

APO RESEARCH · REPORT

Pulmonary Fibrosis Drug

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Pulmonary Fibrosis Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

2 January 2026195 pages

Choose your research edition.

Industry ResearchPulmonary Fibrosis Drug Industry Research Report 2026125 pages · $2,950 USDIndustry Growth & TrendsGlobal Pulmonary Fibrosis Drug Industry Growth and Trends Forecast to 2032107 pages · $3,450 USDMarket StructureGlobal Pulmonary Fibrosis Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Pulmonary Fibrosis Drug Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Pulmonary Fibrosis Drug Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The global Pulmonary Fibrosis Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Pulmonary Fibrosis Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Pulmonary Fibrosis Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Pulmonary Fibrosis Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Pulmonary Fibrosis Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Pulmonary Fibrosis Drug include Merck & Co., Inc., Roche, MediciNova, Inc., Genentech, Inc., Galapagos NV, FibroGen, Inc., Cipla Inc., Bristol-Myers Squibb Company and Boehringer Ingelheim, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Pulmonary Fibrosis Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Pulmonary Fibrosis Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Pulmonary Fibrosis Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Pulmonary Fibrosis Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Pulmonary Fibrosis Drug Segment by Company

Merck & Co., Inc.

Roche

MediciNova, Inc.

Genentech, Inc.

Galapagos NV

FibroGen, Inc.

Cipla Inc.

Bristol-Myers Squibb Company

Boehringer Ingelheim

Biogen

Pulmonary Fibrosis Drug Segment by Type

Pirfenidone

Nintedanib

Pulmonary Fibrosis Drug Segment by Application

Hospital

Clinic

Pulmonary Fibrosis Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pulmonary Fibrosis Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Pulmonary Fibrosis Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pulmonary Fibrosis Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Pulmonary Fibrosis Drug market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Pulmonary Fibrosis Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Pulmonary Fibrosis Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Pulmonary Fibrosis Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Pulmonary Fibrosis Drug Industry Trends Table 2. Pulmonary Fibrosis Drug Industry Drivers Table 3. Pulmonary Fibrosis Drug Industry Opportunities and Challenges Table 4. Pulmonary Fibrosis Drug Industry Restraints Table 5. Global Pulmonary Fibrosis Drug Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Pulmonary Fibrosis Drug Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Pulmonary Fibrosis Drug Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Pulmonary Fibrosis Drug Sales Market Share by Manufacturers Table 9. Global Pulmonary Fibrosis Drug Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Pulmonary Fibrosis Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Pulmonary Fibrosis Drug Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Pulmonary Fibrosis Drug Manufacturers, Product Type & Application Table 13. Global Pulmonary Fibrosis Drug Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Pulmonary Fibrosis Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Pirfenidone Table 17. Major Manufacturers of Nintedanib Table 18. Global Pulmonary Fibrosis Drug Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 19. Global Pulmonary Fibrosis Drug Sales by Type (2021-2026) & (K Units) Table 20. Global Pulmonary Fibrosis Drug Sales by Type (2027-2032) & (K Units) Table 21. Global Pulmonary Fibrosis Drug Sales Market Share by Type (2021-2026) Table 22. Global Pulmonary Fibrosis Drug Sales Market Share by Type (2027-2032) Table 23. Global Pulmonary Fibrosis Drug Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 24. Global Pulmonary Fibrosis Drug Revenue by Type (2021-2026) & (K Units) Table 25. Global Pulmonary Fibrosis Drug Revenue by Type (2027-2032) & (K Units) Table 26. Global Pulmonary Fibrosis Drug Revenue Market Share by Type (2021-2026) Table 27. Global Pulmonary Fibrosis Drug Revenue Market Share by Type (2027-2032) Table 28. Major Manufacturers of Hospital Table 29. Major Manufacturers of Clinic Table 30. Global Pulmonary Fibrosis Drug Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 31. Global Pulmonary Fibrosis Drug Sales by Application (2021-2026) & (K Units) Table 32. Global Pulmonary Fibrosis Drug Sales by Application (2027-2032) & (K Units) Table 33. Global Pulmonary Fibrosis Drug Sales Market Share by Application (2021-2026) Table 34. Global Pulmonary Fibrosis Drug Sales Market Share by Application (2027-2032) Table 35. Global Pulmonary Fibrosis Drug Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 36. Global Pulmonary Fibrosis Drug Revenue by Application (2021-2026) & (K Units) Table 37. Global Pulmonary Fibrosis Drug Revenue by Application (2027-2032) & (K Units) Table 38. Global Pulmonary Fibrosis Drug Revenue Market Share by Application (2021-2026) Table 39. Global Pulmonary Fibrosis Drug Revenue Market Share by Application (2027-2032) Table 40. Global Pulmonary Fibrosis Drug Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 41. Global Pulmonary Fibrosis Drug Sales by Region (2021-2026) & (K Units) Table 42. Global Pulmonary Fibrosis Drug Sales Market Share by Region (2021-2026) Table 43. Global Pulmonary Fibrosis Drug Sales Forecasted by Region (2027-2032) & (K Units) Table 44. Global Pulmonary Fibrosis Drug Sales Forecasted Market Share by Region (2027-2032) Table 45. North America Pulmonary Fibrosis Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 46. North America Pulmonary Fibrosis Drug Sales by Country (2021-2026) & (K Units) Table 47. North America Pulmonary Fibrosis Drug Sales by Country (2027-2032) & (K Units) Table 48. Europe Pulmonary Fibrosis Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 49. Europe Pulmonary Fibrosis Drug Sales by Country (2021-2026) & (K Units) Table 50. Europe Pulmonary Fibrosis Drug Sales by Country (2027-2032) & (K Units) Table 51. Asia Pacific Pulmonary Fibrosis Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 52. Asia Pacific Pulmonary Fibrosis Drug Sales by Country (2021-2026) & (K Units) Table 53. Asia Pacific Pulmonary Fibrosis Drug Sales by Country (2027-2032) & (K Units) Table 54. South America, Middle East and Africa Pulmonary Fibrosis Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 55. South America, Middle East and Africa Pulmonary Fibrosis Drug Sales by Country (2021-2026) & (K Units) Table 56. South America, Middle East and Africa Pulmonary Fibrosis Drug Sales by Country (2027-2032) & (K Units) Table 57. Global Pulmonary Fibrosis Drug Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 58. Global Pulmonary Fibrosis Drug Revenue by Region (2021-2026) & (US$ Million) Table 59. Global Pulmonary Fibrosis Drug Revenue by Region (2027-2032) & (US$ Million) Table 60. Global Pulmonary Fibrosis Drug Revenue Market Share by Region (2021-2026) Table 61. Global Pulmonary Fibrosis Drug Revenue Market Share by Region (2027-2032) Table 62. Merck & Co., Inc. Company Information Table 63. Merck & Co., Inc. Business Overview Table 64. Merck & Co., Inc. Pulmonary Fibrosis Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 65. Merck & Co., Inc. Pulmonary Fibrosis Drug Product Portfolio Table 66. Merck & Co., Inc. Recent Development Table 67. Roche Company Information Table 68. Roche Business Overview Table 69. Roche Pulmonary Fibrosis Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. Roche Pulmonary Fibrosis Drug Product Portfolio Table 71. Roche Recent Development Table 72. MediciNova, Inc. Company Information Table 73. MediciNova, Inc. Business Overview Table 74. MediciNova, Inc. Pulmonary Fibrosis Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. MediciNova, Inc. Pulmonary Fibrosis Drug Product Portfolio Table 76. MediciNova, Inc. Recent Development Table 77. Genentech, Inc. Company Information Table 78. Genentech, Inc. Business Overview Table 79. Genentech, Inc. Pulmonary Fibrosis Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. Genentech, Inc. Pulmonary Fibrosis Drug Product Portfolio Table 81. Genentech, Inc. Recent Development Table 82. Galapagos NV Company Information Table 83. Galapagos NV Business Overview Table 84. Galapagos NV Pulmonary Fibrosis Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 85. Galapagos NV Pulmonary Fibrosis Drug Product Portfolio Table 86. Galapagos NV Recent Development Table 87. FibroGen, Inc. Company Information Table 88. FibroGen, Inc. Business Overview Table 89. FibroGen, Inc. Pulmonary Fibrosis Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 90. FibroGen, Inc. Pulmonary Fibrosis Drug Product Portfolio Table 91. FibroGen, Inc. Recent Development Table 92. Cipla Inc. Company Information Table 93. Cipla Inc. Business Overview Table 94. Cipla Inc. Pulmonary Fibrosis Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 95. Cipla Inc. Pulmonary Fibrosis Drug Product Portfolio Table 96. Cipla Inc. Recent Development Table 97. Bristol-Myers Squibb Company Company Information Table 98. Bristol-Myers Squibb Company Business Overview Table 99. Bristol-Myers Squibb Company Pulmonary Fibrosis Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 100. Bristol-Myers Squibb Company Pulmonary Fibrosis Drug Product Portfolio Table 101. Bristol-Myers Squibb Company Recent Development Table 102. Boehringer Ingelheim Company Information Table 103. Boehringer Ingelheim Business Overview Table 104. Boehringer Ingelheim Pulmonary Fibrosis Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 105. Boehringer Ingelheim Pulmonary Fibrosis Drug Product Portfolio Table 106. Boehringer Ingelheim Recent Development Table 107. Biogen Company Information Table 108. Biogen Business Overview Table 109. Biogen Pulmonary Fibrosis Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 110. Biogen Pulmonary Fibrosis Drug Product Portfolio Table 111. Biogen Recent Development Table 112. Key Raw Materials Table 113. Raw Materials Key Suppliers Table 114. Pulmonary Fibrosis Drug Distributors List Table 115. Pulmonary Fibrosis Drug Customers List Table 116. Research Programs/Design for This Report Table 117. Authors List of This Report Table 118. Secondary Sources Table 119. Primary Sources List of Figures Figure 1. Pulmonary Fibrosis Drug Product Image Figure 2. Global Pulmonary Fibrosis Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Pulmonary Fibrosis Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Pulmonary Fibrosis Drug Sales (2021-2032) & (K Units) Figure 5. Global Pulmonary Fibrosis Drug Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Pulmonary Fibrosis Drug Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Pirfenidone Image Figure 9. Nintedanib Image Figure 10. Global Pulmonary Fibrosis Drug Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 11. Global Pulmonary Fibrosis Drug Sales Market Share 2021 VS 2025 VS 2032 Figure 12. Global Pulmonary Fibrosis Drug Sales Market Share by Type (2021-2032) Figure 13. Global Pulmonary Fibrosis Drug Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global Pulmonary Fibrosis Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 15. Global Pulmonary Fibrosis Drug Revenue Market Share by Type (2021-2032) Figure 16. Hospital Image Figure 17. Clinic Image Figure 18. Global Pulmonary Fibrosis Drug Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 19. Global Pulmonary Fibrosis Drug Sales Market Share 2021 VS 2025 VS 2032 Figure 20. Global Pulmonary Fibrosis Drug Sales Market Share by Application (2021-2032) Figure 21. Global Pulmonary Fibrosis Drug Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 22. Global Pulmonary Fibrosis Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 23. Global Pulmonary Fibrosis Drug Revenue Market Share by Application (2021-2032) Figure 24. North America Pulmonary Fibrosis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 25. North America Pulmonary Fibrosis Drug Sales Market Share by Country (2021-2032) Figure 26. U.S. Pulmonary Fibrosis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 27. Canada Pulmonary Fibrosis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 28. Mexico Pulmonary Fibrosis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 29. Europe Pulmonary Fibrosis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 30. Europe Pulmonary Fibrosis Drug Sales Market Share by Country (2021-2032) Figure 31. Germany Pulmonary Fibrosis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 32. France Pulmonary Fibrosis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 33. U.K. Pulmonary Fibrosis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 34. Italy Pulmonary Fibrosis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 35. Netherlands Pulmonary Fibrosis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 36. Asia Pacific Pulmonary Fibrosis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 37. Asia Pacific Pulmonary Fibrosis Drug Sales Market Share by Country (2021-2032) Figure 38. China Pulmonary Fibrosis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Japan Pulmonary Fibrosis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 40. South Korea Pulmonary Fibrosis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Southeast Asia Pulmonary Fibrosis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 42. India Pulmonary Fibrosis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 43. Australia Pulmonary Fibrosis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 44. South America, Middle East and Africa Pulmonary Fibrosis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 45. South America, Middle East and Africa Pulmonary Fibrosis Drug Sales Market Share by Country (2021-2032) Figure 46. Brazil Pulmonary Fibrosis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 47. South Africa Pulmonary Fibrosis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 48. Saudi Arabia Pulmonary Fibrosis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 49. Turkey Pulmonary Fibrosis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 50. Argentina Pulmonary Fibrosis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 51. UAE Pulmonary Fibrosis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 52. Egypt Pulmonary Fibrosis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Chile Pulmonary Fibrosis Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Global Pulmonary Fibrosis Drug Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 55. Global Pulmonary Fibrosis Drug Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 56. North America Pulmonary Fibrosis Drug Revenue (2021-2032) & (US$ Million) Figure 57. North America Pulmonary Fibrosis Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 58. Europe Pulmonary Fibrosis Drug Revenue (2021-2032) & (US$ Million) Figure 59. Europe Pulmonary Fibrosis Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 60. Asia-Pacific Pulmonary Fibrosis Drug Revenue (2021-2032) & (US$ Million) Figure 61. Asia-Pacific Pulmonary Fibrosis Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. South America, Middle East and Africa Pulmonary Fibrosis Drug Revenue (2021-2032) & (US$ Million) Figure 63. South America, Middle East and Africa Pulmonary Fibrosis Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. Pulmonary Fibrosis Drug Value Chain Figure 65. Manufacturing Cost Structure Figure 66. Pulmonary Fibrosis Drug Production Mode & Process Figure 67. Direct Comparison with Distribution Share Figure 68. Distributors Profiles Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • Pirfenidone
  • Nintedanib
Applications
  • Hospital
  • Clinic
Companies covered
  • Merck & Co., Inc.
  • Roche
  • MediciNova, Inc.
  • Genentech, Inc.
  • Galapagos NV
  • FibroGen, Inc.
  • Cipla Inc.
  • Bristol-Myers Squibb Company
  • Boehringer Ingelheim
  • Biogen

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Pulmonary Fibrosis Drug Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Pulmonary Fibrosis Drug Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Pulmonary Fibrosis Drug Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Pulmonary Fibrosis Drug Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Pulmonary Fibrosis Drug Market Dynamics
  1. 2.1 Pulmonary Fibrosis Drug Industry Trends
  2. 2.2 Pulmonary Fibrosis Drug Industry Drivers
  3. 2.3 Pulmonary Fibrosis Drug Industry Opportunities and Challenges
  4. 2.4 Pulmonary Fibrosis Drug Industry Restraints
3 Pulmonary Fibrosis Drug Market by Manufacturers
  1. 3.1 Global Pulmonary Fibrosis Drug Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Pulmonary Fibrosis Drug Sales by Manufacturers (2021-2026)
  3. 3.3 Global Pulmonary Fibrosis Drug Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Pulmonary Fibrosis Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Pulmonary Fibrosis Drug Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Pulmonary Fibrosis Drug Manufacturers, Product Type & Application
  7. 3.7 Global Pulmonary Fibrosis Drug Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Pulmonary Fibrosis Drug Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Pulmonary Fibrosis Drug Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Pulmonary Fibrosis Drug Tier 1, Tier 2, and Tier 3
4 Pulmonary Fibrosis Drug Market by Type
  1. 4.1 Pulmonary Fibrosis Drug Type Introduction
  2. 4.1.1 Pirfenidone
  3. 4.1.2 Nintedanib
  4. 4.2 Global Pulmonary Fibrosis Drug Sales by Type
  5. 4.2.1 Global Pulmonary Fibrosis Drug Sales by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Pulmonary Fibrosis Drug Sales by Type (2021-2032)
  7. 4.2.3 Global Pulmonary Fibrosis Drug Sales Market Share by Type (2021-2032)
  8. 4.3 Global Pulmonary Fibrosis Drug Revenue by Type
  9. 4.3.1 Global Pulmonary Fibrosis Drug Revenue by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Pulmonary Fibrosis Drug Revenue by Type (2021-2032)
  11. 4.3.3 Global Pulmonary Fibrosis Drug Revenue Market Share by Type (2021-2032)
5 Pulmonary Fibrosis Drug Market by Application
  1. 5.1 Pulmonary Fibrosis Drug Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.2 Global Pulmonary Fibrosis Drug Sales by Application
  5. 5.2.1 Global Pulmonary Fibrosis Drug Sales by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Pulmonary Fibrosis Drug Sales by Application (2021-2032)
  7. 5.2.3 Global Pulmonary Fibrosis Drug Sales Market Share by Application (2021-2032)
  8. 5.3 Global Pulmonary Fibrosis Drug Revenue by Application
  9. 5.3.1 Global Pulmonary Fibrosis Drug Revenue by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Pulmonary Fibrosis Drug Revenue by Application (2021-2032)
  11. 5.3.3 Global Pulmonary Fibrosis Drug Revenue Market Share by Application (2021-2032)
6 Global Pulmonary Fibrosis Drug Sales by Region
  1. 6.1 Global Pulmonary Fibrosis Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Pulmonary Fibrosis Drug Sales by Region (2021-2032)
  3. 6.2.1 Global Pulmonary Fibrosis Drug Sales by Region (2021-2026)
  4. 6.2.2 Global Pulmonary Fibrosis Drug Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Pulmonary Fibrosis Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Pulmonary Fibrosis Drug Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Pulmonary Fibrosis Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Pulmonary Fibrosis Drug Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Pulmonary Fibrosis Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Pulmonary Fibrosis Drug Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Pulmonary Fibrosis Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Pulmonary Fibrosis Drug Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Pulmonary Fibrosis Drug Revenue by Region
  1. 7.1 Global Pulmonary Fibrosis Drug Revenue by Region
  2. 7.1.1 Global Pulmonary Fibrosis Drug Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Pulmonary Fibrosis Drug Revenue by Region (2021-2026)
  4. 7.1.3 Global Pulmonary Fibrosis Drug Revenue by Region (2027-2032)
  5. 7.1.4 Global Pulmonary Fibrosis Drug Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Pulmonary Fibrosis Drug Revenue (2021-2032)
  8. 7.2.2 North America Pulmonary Fibrosis Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Pulmonary Fibrosis Drug Revenue (2021-2032)
  11. 7.3.2 Europe Pulmonary Fibrosis Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Pulmonary Fibrosis Drug Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Pulmonary Fibrosis Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Pulmonary Fibrosis Drug Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Pulmonary Fibrosis Drug Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Merck & Co., Inc.
  2. 8.1.1 Merck & Co., Inc. Company Information
  3. 8.1.2 Merck & Co., Inc. Business Overview
  4. 8.1.3 Merck & Co., Inc. Pulmonary Fibrosis Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Merck & Co., Inc. Pulmonary Fibrosis Drug Product Portfolio
  6. 8.1.5 Merck & Co., Inc. Recent Developments
  7. 8.2 Roche
  8. 8.2.1 Roche Company Information
  9. 8.2.2 Roche Business Overview
  10. 8.2.3 Roche Pulmonary Fibrosis Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Roche Pulmonary Fibrosis Drug Product Portfolio
  12. 8.2.5 Roche Recent Developments
  13. 8.3 MediciNova, Inc.
  14. 8.3.1 MediciNova, Inc. Company Information
  15. 8.3.2 MediciNova, Inc. Business Overview
  16. 8.3.3 MediciNova, Inc. Pulmonary Fibrosis Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 MediciNova, Inc. Pulmonary Fibrosis Drug Product Portfolio
  18. 8.3.5 MediciNova, Inc. Recent Developments
  19. 8.4 Genentech, Inc.
  20. 8.4.1 Genentech, Inc. Company Information
  21. 8.4.2 Genentech, Inc. Business Overview
  22. 8.4.3 Genentech, Inc. Pulmonary Fibrosis Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Genentech, Inc. Pulmonary Fibrosis Drug Product Portfolio
  24. 8.4.5 Genentech, Inc. Recent Developments
  25. 8.5 Galapagos NV
  26. 8.5.1 Galapagos NV Company Information
  27. 8.5.2 Galapagos NV Business Overview
  28. 8.5.3 Galapagos NV Pulmonary Fibrosis Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Galapagos NV Pulmonary Fibrosis Drug Product Portfolio
  30. 8.5.5 Galapagos NV Recent Developments
  31. 8.6 FibroGen, Inc.
  32. 8.6.1 FibroGen, Inc. Company Information
  33. 8.6.2 FibroGen, Inc. Business Overview
  34. 8.6.3 FibroGen, Inc. Pulmonary Fibrosis Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 FibroGen, Inc. Pulmonary Fibrosis Drug Product Portfolio
  36. 8.6.5 FibroGen, Inc. Recent Developments
  37. 8.7 Cipla Inc.
  38. 8.7.1 Cipla Inc. Company Information
  39. 8.7.2 Cipla Inc. Business Overview
  40. 8.7.3 Cipla Inc. Pulmonary Fibrosis Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Cipla Inc. Pulmonary Fibrosis Drug Product Portfolio
  42. 8.7.5 Cipla Inc. Recent Developments
  43. 8.8 Bristol-Myers Squibb Company
  44. 8.8.1 Bristol-Myers Squibb Company Company Information
  45. 8.8.2 Bristol-Myers Squibb Company Business Overview
  46. 8.8.3 Bristol-Myers Squibb Company Pulmonary Fibrosis Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Bristol-Myers Squibb Company Pulmonary Fibrosis Drug Product Portfolio
  48. 8.8.5 Bristol-Myers Squibb Company Recent Developments
  49. 8.9 Boehringer Ingelheim
  50. 8.9.1 Boehringer Ingelheim Company Information
  51. 8.9.2 Boehringer Ingelheim Business Overview
  52. 8.9.3 Boehringer Ingelheim Pulmonary Fibrosis Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Boehringer Ingelheim Pulmonary Fibrosis Drug Product Portfolio
  54. 8.9.5 Boehringer Ingelheim Recent Developments
  55. 8.10 Biogen
  56. 8.10.1 Biogen Company Information
  57. 8.10.2 Biogen Business Overview
  58. 8.10.3 Biogen Pulmonary Fibrosis Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Biogen Pulmonary Fibrosis Drug Product Portfolio
  60. 8.10.5 Biogen Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Pulmonary Fibrosis Drug Value Chain Analysis
  2. 9.1.1 Pulmonary Fibrosis Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Pulmonary Fibrosis Drug Production Mode & Process
  6. 9.2 Pulmonary Fibrosis Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Pulmonary Fibrosis Drug Distributors
  9. 9.2.3 Pulmonary Fibrosis Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst